AR006833A1 - Compuestos de beta lactama monociclicos, composicion farmaceutica que los contiene, uso de dichos compuestos para preparar medicamentos, procedimientopara preparar dichos compuestos, compuestos intermediarios y procedimientos para preparar dichos compuestos intermediarios. - Google Patents

Compuestos de beta lactama monociclicos, composicion farmaceutica que los contiene, uso de dichos compuestos para preparar medicamentos, procedimientopara preparar dichos compuestos, compuestos intermediarios y procedimientos para preparar dichos compuestos intermediarios.

Info

Publication number
AR006833A1
AR006833A1 ARP970101682A ARP970101682A AR006833A1 AR 006833 A1 AR006833 A1 AR 006833A1 AR P970101682 A ARP970101682 A AR P970101682A AR P970101682 A ARP970101682 A AR P970101682A AR 006833 A1 AR006833 A1 AR 006833A1
Authority
AR
Argentina
Prior art keywords
compounds
prepare
procedures
pharmaceutical composition
composition containing
Prior art date
Application number
ARP970101682A
Other languages
English (en)
Spanish (es)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9608646.7A external-priority patent/GB9608646D0/en
Priority claimed from GBGB9623756.5A external-priority patent/GB9623756D0/en
Priority claimed from GBGB9625121.0A external-priority patent/GB9625121D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of AR006833A1 publication Critical patent/AR006833A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP970101682A 1996-04-26 1997-04-24 Compuestos de beta lactama monociclicos, composicion farmaceutica que los contiene, uso de dichos compuestos para preparar medicamentos, procedimientopara preparar dichos compuestos, compuestos intermediarios y procedimientos para preparar dichos compuestos intermediarios. AR006833A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9608646.7A GB9608646D0 (en) 1996-04-26 1996-04-26 Novel compounds
GBGB9623756.5A GB9623756D0 (en) 1996-11-15 1996-11-15 Novel compounds
GBGB9625121.0A GB9625121D0 (en) 1996-12-03 1996-12-03 Novel compounds

Publications (1)

Publication Number Publication Date
AR006833A1 true AR006833A1 (es) 1999-09-29

Family

ID=27268259

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970101682A AR006833A1 (es) 1996-04-26 1997-04-24 Compuestos de beta lactama monociclicos, composicion farmaceutica que los contiene, uso de dichos compuestos para preparar medicamentos, procedimientopara preparar dichos compuestos, compuestos intermediarios y procedimientos para preparar dichos compuestos intermediarios.

Country Status (17)

Country Link
EP (1) EP0915843A1 (no)
JP (1) JP2000509049A (no)
AR (1) AR006833A1 (no)
AU (1) AU2698697A (no)
BR (1) BR9709196A (no)
CA (1) CA2252696A1 (no)
CZ (1) CZ341098A3 (no)
HU (1) HUP9901359A3 (no)
ID (1) ID16660A (no)
IL (1) IL126696A0 (no)
MA (1) MA26426A1 (no)
NO (1) NO984939L (no)
NZ (1) NZ332476A (no)
PE (1) PE64398A1 (no)
PL (1) PL329530A1 (no)
TR (1) TR199802160T2 (no)
WO (1) WO1997041098A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0108396B1 (pt) * 2000-02-16 2015-05-19 Smithkline Beecham Plc Derivados de pirimidina-4-ona como inibidores de ldl-pla2
BRPI0208384B1 (pt) 2001-03-28 2016-05-31 Merck Sharp & Dohme síntese enantiosseletiva de compostos intermediários de azetidinona
ES2275007T3 (es) * 2001-05-25 2007-06-01 Schering Corporation Uso de derivados de azetidinona sustitudos en el tratamiento de la enfermedad de alzeimer.
US9029383B2 (en) 2007-05-11 2015-05-12 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
US8962633B2 (en) 2007-05-11 2015-02-24 Thomas Jefferson University Methods of treatment and prevention of metabolic bone diseases and disorders
EP2977452A3 (en) 2007-05-11 2016-05-25 Thomas Jefferson University Methods of treatment and prevention of neurodegenerative diseases and disorders
US20130252963A1 (en) 2010-12-06 2013-09-26 Yun Jin Pyrimidinone compounds for use in the treatment of disease or conditions mediated by lp-pla2
JP2013545792A (ja) 2010-12-17 2013-12-26 グラクソ グループ リミテッド 眼疾患の処置および防止方法
WO2013000267A1 (zh) 2011-06-27 2013-01-03 中国科学院上海药物研究所 唑类杂环化合物、其制备方法、药物组合物和用途
AU2012289492B2 (en) 2011-07-27 2016-02-04 Glaxo Group Limited 2,3-dihydroimidazo[1,2-c] pyrimidin-5(1H)-one compounds use as Lp-PLA2 inhibitors
AR087309A1 (es) 2011-07-27 2014-03-12 Glaxo Group Ltd Compuesto heterociclico de anillos condensados sustituido, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento para el tratamiento de enfermedades neurogenerativas y aterosclerosis
CA2899143A1 (en) 2013-01-25 2014-07-31 Glaxosmithkline Intellectual Property Development Limited Bicyclic pyrimidone compounds as inhibitors of lp-pla2
BR112015017759B1 (pt) 2013-01-25 2022-05-24 Glaxosmithkline Intellectual Property Development Limited Compostos inibidores de fosfolipase a2 associada à lipoproteína (lp-pla2) à base de 2,3-dihidroimidazol[1,2-c]pirimidin5(1h)-ona, e composição farmacêutica compreendendo tais compostos
JP2016508995A (ja) 2013-01-25 2016-03-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 化合物
WO2016012916A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
WO2016012917A1 (en) 2014-07-22 2016-01-28 Glaxosmithkline Intellectual Property Development Limited 1,2,3,5-tetrahydroimidazo[1,2-c]pyrimidine derivatives useful in the treatment of diseases and disorders mediated by lp-pla2
CA3156783A1 (en) 2019-11-09 2021-05-14 Yun Jin Tricycle dihydroimidazopyrimidone derivative, preparation method thereof, pharmaceutical composition and use thereof
CN115304620A (zh) 2021-05-07 2022-11-08 上海赛默罗生物科技有限公司 嘧啶酮衍生物、其制备方法、药物组合物和用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
IL89835A0 (en) * 1988-04-11 1989-12-15 Merck & Co Inc Substituted azetidinones,their preparation and pharmaceutical compositions containing them
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
WO1993000332A1 (en) * 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1993002048A1 (en) * 1991-07-23 1993-02-04 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
TW275621B (no) * 1992-10-27 1996-05-11 Merck & Co Inc
WO1994013636A1 (en) * 1992-12-17 1994-06-23 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
JPH08500740A (ja) * 1993-06-25 1996-01-30 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー リポタンパク質関連ホスホリパーゼａ▲下２▼、その阻害剤および診断および治療におけるその使用
ES2159573T3 (es) * 1993-10-06 2001-10-16 Icos Corp Acetilhidrolasa del factor activador de plaquetas.
GB9421816D0 (en) * 1994-10-29 1994-12-14 Smithkline Beecham Plc Novel compounds
MX9704736A (es) * 1994-12-22 1997-10-31 Smithkline Beecham Plc Acetidin 2-onas sustituidas, procedimiento para prepararlas, uso de las mismas y composiciones que las contienen.
AU5014496A (en) * 1995-03-23 1996-10-08 Japan Tobacco Inc. Diphenylmethyl-azetidinone compounds and elastase inhibitor
CN1197452A (zh) * 1995-07-01 1998-10-28 史密丝克莱恩比彻姆有限公司 用于治疗动脉粥样硬化的氮杂环丁烷酮衍生物
WO1997021676A1 (en) * 1995-12-08 1997-06-19 Smithkline Beecham Plc Azetidinone compounds for the treatment of atherosclerosis

Also Published As

Publication number Publication date
MA26426A1 (fr) 2004-12-20
HUP9901359A2 (hu) 1999-08-30
CZ341098A3 (cs) 1999-03-17
PE64398A1 (es) 1999-01-06
NZ332476A (en) 2000-06-23
CA2252696A1 (en) 1997-11-06
JP2000509049A (ja) 2000-07-18
NO984939D0 (no) 1998-10-23
IL126696A0 (en) 1999-08-17
HUP9901359A3 (en) 2000-03-28
WO1997041098A1 (en) 1997-11-06
PL329530A1 (en) 1999-03-29
AU2698697A (en) 1997-11-19
BR9709196A (pt) 1999-05-25
ID16660A (id) 1997-10-30
NO984939L (no) 1998-12-23
EP0915843A1 (en) 1999-05-19
TR199802160T2 (xx) 1999-04-21

Similar Documents

Publication Publication Date Title
AR006833A1 (es) Compuestos de beta lactama monociclicos, composicion farmaceutica que los contiene, uso de dichos compuestos para preparar medicamentos, procedimientopara preparar dichos compuestos, compuestos intermediarios y procedimientos para preparar dichos compuestos intermediarios.
ES2161291T3 (es) N-(indol-2-carbonil)amidas y derivados como inhibidores de la glucogeno fosforilasa.
RU94038064A (ru) Производные пиперазина и пиперидина, их применение в качестве противопсихотических средств, способ их получения фармацевтическая композиция
AR005357A1 (es) Derivados de 14-o-carbamoil mutilina y sus sales utiles en el tratamiento de infecciones bacterianas, procedimiento para prepararlas, composicionesfarmaceuticas formuladas con dichos derivados y uso de los mismos para preparar dichas composiciones
IL151172A0 (en) Amine derivatives, their preparation and use as bax modulators
EA200000592A1 (ru) Азаполициклические соединения, конденсированные с арилом
MX9804107A (es) Derivados de quinolina.
EA200100983A1 (ru) Производные 13-метилэритромицина
FI875229A (fi) Menetelmä uusien farmakologisesti aktiivisten katekolijohdoksien valmistamiseksi
GEP20033028B (en) Heterocyclic Compounds as Inhibitors of Rotamase Enzymes, Method for Their Production, Pharmaceutical Composition Containing Them and Use Thereof
IL110151A0 (en) Amide and urea derivatives and pharmaceutical compositions containing the same
DE3869173D1 (de) Amino 5,6,7,8-tetrahydronaphtho(2,3b)furanderivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
DK0736029T3 (da) Antikonvulsive pseudofructopyranosesulfamater
BG103426A (en) Derivatives of substituted 4-biphenyl-4-hydroxy-oil acids as inhibitors of matrix metalloproteases
MX9400253A (es) Derivados de piperazina, proceso para su preparacion y composiciones farmaceuticas que los contienen.
PT94957A (pt) Processo para preparacao de composicoes farmaceuticas para tratamento da hipertrofia e hiperplasia cardiais e vasculares compreendendo um inibidor do enzima de conversao da angiotensina
EA199800155A1 (ru) Новое соединение
UY24697A1 (es) Metodos para producir inhibidores de vih-proteasa y productos intermedios para producir inhibidores de vih-proteasa
MX9400165A (es) Derivados de ter-butilergolina, proceso para su produccion y composiciones farmaceuticas que los contienen.
FR2707089B1 (fr) Nouveaux dérivés d'acide phosphonique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
EA199800701A1 (ru) БЕНЗО[С]ХИНОЛИЗИНОВЫЕ ПРОИЗВОДНЫЕ, ИХ ПОЛУЧЕНИЕ И ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ 5a-РЕДУКТАЗ
ATE116647T1 (de) Thiophenderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen.
ES2075180T3 (es) Nuevos derivados de la piridona, su procedimiento de preparacion, los nuevos productos intermedios obtenidos, su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen.
SE9703056L (sv) Klavulansyrasalter, förfarande för framställning därav och farmaceutiska kompositioner innehållande dem
RU94036769A (ru) Алкильные производные тразодона, способ их получения, промежуточные соединения и фармацевтическая композиция